Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES TAKEDA<br />
Product Class Date Terms of Agreement<br />
Omacor (TAK 085) A 2005 Takeda licensed the Japanese rights to Omacor from<br />
Pronova.<br />
Matuzumab L 2005 Takeda signed a co-development and co-promotion<br />
agreement for matuzumab with originator Merck KGaA in<br />
September 2005.<br />
Ilaprazole A 2005 Il Yang licensed worldwide rights to ilaprazole, a proton<br />
pump inhibitor, outside South Korea and China, to TAP.<br />
R 851 J 2005 Collaboration to jointly develop and market 3Ms topical<br />
immune response modifier. Takeda has acquired<br />
exclusive Japan/Asia region rights. In 2007 this<br />
agreement was updated granting Takeda full rights to the<br />
drug from 3M.<br />
GnRH analogue, Norwood<br />
Immunology/TAP<br />
L 2005 TAP and Norwood Immunology are jointly developing<br />
GnRH analogues, which have potential in bone marrow<br />
transplants, cancer and HIV infection.<br />
TAK 363/TRK 130 G 2005 A compound for the treatment of urinary incontinence,<br />
co-developed by Takeda and Toray. Toray will market it<br />
in Japan and Takeda will market it in overseas territories.<br />
It was discovered in Toray’s compound library through<br />
joint research by both companies<br />
Idebenone N 2005 Collaborative deal with regarding development of<br />
Santhera’s idebenone, a small molecule with potential in<br />
the treatment of Friedreich’s ataxia. Santhera will<br />
conduct all clinical development to gain regulatory<br />
approval in Europe and the USA. Takeda will support<br />
development and obtain an exclusive marketing license in<br />
the EU and Switzerland. Santhera plans to market<br />
idebenone independently in the USA. In August 2007<br />
Santhera granted Takeda marketing rights in the EU and<br />
Switzerland to idebenone for the treatment of Duchenne<br />
Muscular Dystrophy (DMD).<br />
Amitiza (lubiprostone) A 2004 Takeda agreed to jointly market lubiprostone in the USA<br />
and Canada with originator Sucampo Takeda also<br />
acquired an option to lubipristone in other territories,<br />
such as Japan and Europe.<br />
Arxxant (ruboxistaurin) A 2003 Takeda signed an agreement with Lilly for joint<br />
development and co-marketing of the product in Japan.<br />
cetilistat (ATL 962) A 2003 Alizyme granted Takeda exclusive rights to develop,<br />
manufacture and market in Japan.<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 97
Change language